Marlana Orloff

TitleAsst Professor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address925 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Schoenberg E, Colombe B, Cha J, Orloff M, Shalabi D, Ross NA, Dasgeb B. Pemphigus associated with ipilimumab therapy. Int J Dermatol. 2021 Jan 07. PMID: 33410503.
      Citations:    
    2. Orloff M, Brennan M, Sato S, Shields CL, Shields JA, Lally S, Mashayekhi A, Mason J, Materin M, Mastrangelo M, Sato T. Unique geospatial accumulations of uveal melanoma. Am J Ophthalmol. 2020 Jul 15. PMID: 32681908.
      Citations:    
    3. Shields CL, Lally SE, Orloff M. Controlling Conjunctival Melanoma-To Infinity and Beyond. JAMA Ophthalmol. 2020 Mar 26. PMID: 32215607.
      Citations:    
    4. Terai M, Londin E, Rochani A, Link E, Lam B, Kaushal G, Bhushan A, Orloff M, Sato T. Expression of Tryptophan 2,3-Dioxygenase in Metastatic Uveal Melanoma. Cancers (Basel). 2020 Feb 10; 12(2). PMID: 32050636.
      Citations:    
    5. Seedor RS, Eschelman DJ, Gonsalves CF, Adamo RD, Orloff M, Amjad A, Sharpe-Mills E, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis. Cancers (Basel). 2020 Jan 01; 12(1). PMID: 31906411.
      Citations:    
    6. Chang M, Lally SE, Dalvin LA, Orloff MM, Shields CL. Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy. Indian J Ophthalmol. 2019 12; 67(12):2071-2073. PMID: 31755463.
      Citations:    
    7. Gonsalves CF, Eschelman DJ, Adamo RD, Anne PR, Orloff MM, Terai M, Hage AN, Yi M, Chervoneva I, Sato T. A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis. Radiology. 2019 Aug 27; 190199. PMID: 31453767.
      Citations:    
    8. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, Lam BQ, Terai M, Ambrosini G, Carvajal RD, Schwartz G, Sato T, Aplin AE. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019 Feb; 11(2). PMID: 30610113.
      Citations:    
    9. Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina. 2018 Apr 23. PMID: 29689030.
      Citations:    
    10. Orloff M. Melanoma Immunotherapy in the Elderly. Curr Oncol Rep. 2018 Mar 02; 20(2):20. PMID: 29500787.
      Citations:    
    11. Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ, Sato T. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy. 2017 Dec; 9(16):1323-1330. PMID: 29185395.
      Citations:    
    12. Valsecchi ME, Orloff M, Sato R, Chervoneva I, Shields CL, Shields JA, Mastrangelo MJ, Sato T. Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls. Ophthalmology. 2018 Feb; 125(2):210-217. PMID: 28935400.
      Citations:    
    13. Orloff M. Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes. Oncolytic Virother. 2016; 5:91-98. PMID: 27785448.
      Citations:    
    14. Orloff M, Weight R, Valsecchi ME, Sato T. Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity? Rev Recent Clin Trials. 2016; 11(2):81-6. PMID: 27028970.
      Citations:    
    15. Terai M, Mu Z, Eschelman DJ, Gonsalves CF, Kageyama K, Chervoneva I, Orloff M, Weight R, Mastrangelo MJ, Cristofanilli M, Sato T. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015 Nov; 2(11):1821-6. PMID: 26870807.
      Citations:    
    16. Mills TA, Orloff M, Domingo-Vidal M, Cotzia P, Birbe RC, Draganova-Tacheva R, Martinez Cantarin MP, Tuluc M, Martinez-Outschoorn U. Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic Correlates. Semin Oncol. 2015 Dec; 42(6):909-14. PMID: 26615135.
      Citations:    
    17. Orloff M, Valsecchi ME, Sato T. Successes and setbacks of early investigational drugs for melanoma. Expert Opin Investig Drugs. 2015 Aug; 24(8):993-7. PMID: 26068553.
      Citations:    
    18. Lebude B, Orloff M, Coben R. Extensive abdominal aortitis in a patient with Crohn's disease. J Cardiovasc Med (Hagerstown). 2012 Sep; 13(9):587-9. PMID: 22499004.
      Citations:    
    Co-Authors (23)
    Explore
    _
    Same Department Expand Description
    Explore
    _